Cara Therapeutics Q2 2022 Earnings Preview (NASDAQ:CARA)

Sunday, 7 August 2022, 23:35:00
Cara Therapeutics (CARA) is scheduled to announce Q2 earnings results on Monday, August 8th, after market close.The consensus EPS Estimate is -$0.24 (+60.7% Y/Y) and the consensus…
— Seeking Alpha

What Makes Cara Therapeutics Inc. (NASDAQ: CARA) One Of The Best Momentum Picks?

Saturday, 6 August 2022, 17:00:00
Cara Therapeutics Inc. (NASDAQ:CARA) shares, rose in value on Friday, 08/05/22, with the stock price up by 7.95% to the previous day’s close as strong demand from buyers drove the stock to $11.27. Actively observing the price movement in the last trading, the stock closed the session at $10.44, falling within a range of $10.18 … What Makes Cara Therapeutics Inc. (NASDAQ: CARA) One Of The Best Momentum Picks? Read More »
— Stocks Register

Cara Therapeutics, Inc. (CARA) to Present at the Canaccord Genuity 42nd Annual Growth Conference

Wednesday, 3 August 2022, 15:10:44
Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 42nd Annual Growth Conference on Wednesday, August 10, 2022, at 9:30 a.m. ET. A webcast of the presentation can be accessed under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days. About Cara Therapeutics Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s novel KORSUVA™ (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis.
— Marijuana Stocks

Cara Therapeutics to Present at the Canaccord Genuity 42nd Annual Growth Conference

Wednesday, 3 August 2022, 13:00:00
STAMFORD, Conn., Aug. 03, 2022 (GLOBE NEWSWIRE) — Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the Canaccord Genuity 42 nd Annual Growth Conference on Wednesday, August 10, 2022, at 9:30 a.m. ET.
— GlobeNewswire

Top 5 2nd Quarter Trades of RHO CAPITAL PARTNERS INC

Tuesday, 2 August 2022, 01:00:08
Related Stocks: CHPT , ONTF , CARA , CHPT , NGM ,
— GuruFocus